More about

PCSK9 Inhibitor

Clinical Guidance
Lipid Management
Treatment Approaches

PCSK9 Inhibitors

Jennifer G. Robinson, MD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Lipid Management
Treatment Approaches

Nonstatins- Evolving Role in ASCVD Prevention

Jennifer G. Robinson, MD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

News
June 04, 2024
2 min read
Save

Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation

Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation

Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.

News
February 29, 2024
3 min read
Save

Insurers reject PCSK9 inhibitors at a higher rate vs. other cardiometabolic prescriptions

Insurers reject PCSK9 inhibitors at a higher rate vs. other cardiometabolic prescriptions

PCSK9 inhibitors are rejected by insurance providers at a higher rate compared with other guideline-indicated cardiometabolic drugs despite expanded labeling and reduced manufacturer cost, researchers reported.

CME
Video

Webcast: Identifying and Addressing Elevated Sodium Intake to Decrease Cardiovascular Risk

Webcast: Identifying and Addressing Elevated Sodium Intake to Decrease Cardiovascular Risk
1.00 CME
1.00 ANCC
60 MINS
$0 FEE
CME
Multimedia

Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances

Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
1.50 CME
1.50 ANCC
90 MINS
$0 FEE
News
November 17, 2023
3 min read
Save

Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction

Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction

PHILADELPHIA — Recaticimab, a novel anti-PCSK9 drug, conferred significant LDL reductions at 48 weeks in a cohort of patients with mixed hyperlipidemias already on statin therapy, a speaker reported.

News
November 12, 2023
3 min read
Save

Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition

Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition

PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.

News
September 08, 2023
3 min read
Save

Lerodalcibep reduces LDL in well-treated patients with HeFH vs. placebo

Lerodalcibep reduces LDL in well-treated patients with HeFH vs. placebo

Monthly lerodalcibep on top of maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous familial hypercholesterolemia, with a safety profile similar vs. placebo, a speaker reported.

Learn the Heart

Part of the Healio Network

PCSK9 Inhibitors Topic Review

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert;9a]

View more